Glenmark Pharmaceuticals Limited

NSEI:GLENMARK 주식 보고서

시가총액: ₹398.7b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Glenmark Pharmaceuticals 미래 성장

Future 기준 확인 4/6

Glenmark Pharmaceuticals (는) 각각 연간 86.5% 및 12.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 84.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.4% 로 예상됩니다.

주요 정보

94.1%

수익 성장률

87.4%

EPS 성장률

Pharmaceuticals 수익 성장17.3%
매출 성장률12.5%
향후 자기자본 수익률18.9%
애널리스트 커버리지

Good

마지막 업데이트16 Jul 2024

최근 미래 성장 업데이트

Recent updates

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08
Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17
Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28
A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

May 28
A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22
Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Feb 14
Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04
There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Mar 25
If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Jan 18
A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Dec 13
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Oct 10
Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

수익 및 매출 성장 예측

NSEI:GLENMARK - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
3/31/2027174,56921,28917,52827,5882
3/31/2026154,26616,45211,58618,15311
3/31/2025137,99013,0351,5868,95711
3/31/2024118,131-18,990-11,638-2,654N/A
12/31/2023131,575-7,640N/AN/AN/A
9/30/2023137,510-1,2633027,192N/A
6/30/2023136,1442,546N/AN/AN/A
3/31/2023129,9012,9721766,254N/A
12/31/2022126,3558,811N/AN/AN/A
9/30/2022123,4518,305-217,689N/A
6/30/2022121,1738,277N/AN/AN/A
3/31/2022123,0499,4173,18511,087N/A
12/31/2021122,10310,202N/AN/AN/A
9/30/2021118,24810,4645,41112,490N/A
6/30/2021116,14410,226N/AN/AN/A
3/31/2021109,4399,7003,56511,312N/A
12/31/2020107,7789,565N/AN/AN/A
9/30/2020107,4458,9923,94512,296N/A
6/30/2020106,6299,207N/AN/AN/A
3/31/2020106,5737,7604,61013,924N/A
12/31/2019104,3707,173N/AN/AN/A
9/30/2019102,5646,4281,27113,254N/A
6/30/2019100,2277,680N/AN/AN/A
3/31/201998,6559,25087013,242N/A
12/31/201895,5328,863N/AN/AN/A
9/30/201892,0188,721N/AN/AN/A
6/30/201889,0576,716N/AN/AN/A
3/31/201890,7448,0396,03416,481N/A
12/31/201791,9086,420N/AN/AN/A
9/30/201795,05510,083N/AN/AN/A
6/30/201794,89610,233N/AN/AN/A
3/31/201790,7949,160N/A6,574N/A
12/31/201689,31610,402N/AN/AN/A
9/30/201681,7497,508N/AN/AN/A
6/30/201678,4147,292N/AN/AN/A
3/31/201675,7327,021N/A3,448N/A
12/31/201570,3005,697N/AN/AN/A
9/30/201569,5305,141N/AN/AN/A
6/30/201567,2444,814N/AN/AN/A
3/31/201565,5614,753N/A4,817N/A
12/31/201464,8915,078N/AN/AN/A
9/30/201463,9836,092N/AN/AN/A
6/30/201461,8975,984N/AN/AN/A
3/31/201459,4505,423N/A8,537N/A
12/31/201356,4416,660N/AN/AN/A
9/30/201354,2416,627N/AN/AN/A

애널리스트 미래 성장 예측

수입 대 저축률: GLENMARK 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 6.7% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: GLENMARK (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: GLENMARK 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: GLENMARK 의 수익(연간 12.5% ) Indian 시장( 9.5% 보다 빠르게 성장할 것으로 예상됩니다. 9.5% 연간).

고성장 수익: GLENMARK 의 수익(연간 12.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: GLENMARK 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 18.4 %).

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y